Werewolf Therapeutics (HOWL) Projected to Post Earnings on Thursday

Werewolf Therapeutics (NASDAQ:HOWL) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Werewolf Therapeutics to announce earnings of ($0.28) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, July 31, 2026 at 7:00 AM ET.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.36. The business had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $21.00 million. On average, analysts expect Werewolf Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Werewolf Therapeutics Stock Up 0.4%

HOWL stock opened at $0.38 on Wednesday. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $2.38. The company has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $0.59. The firm has a market capitalization of $18.65 million, a P/E ratio of -0.50 and a beta of 0.29.

Insiders Place Their Bets

In other Werewolf Therapeutics news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total transaction of $145,918.85. Following the transaction, the insider owned 303,719 shares in the company, valued at $106,301.65. The trade was a 57.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Luke Evnin sold 107,429 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total transaction of $33,302.99. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,513,385 shares of company stock valued at $982,239. 23.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Vanguard Group Inc. lifted its stake in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after buying an additional 221,766 shares during the period. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $409,000. Finally, Citadel Advisors LLC bought a new position in shares of Werewolf Therapeutics during the third quarter valued at approximately $304,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on HOWL. Weiss Ratings downgraded shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Wall Street Zen raised Werewolf Therapeutics to a “sell” rating in a research note on Saturday, August 1st. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.